66 related articles for article (PubMed ID: 34199287)
1. Purified Tea (
Ren N; Chen L; Li B; Rankin GO; Chen YC; Tu Y
Int J Mol Sci; 2020 Jun; 21(12):. PubMed ID: 32560563
[TBL] [Abstract][Full Text] [Related]
2. Glycyrrhizic acid enhances the anticancer activity of cisplatin in the human ovarian cancer cell line.
Omidi F; Shahbazi S; Reiisi S; Azhdari S; Karimzadeh MR
Toxicol In Vitro; 2023 Dec; 93():105687. PubMed ID: 37659683
[TBL] [Abstract][Full Text] [Related]
3. Genome-Scale CRISPR/Cas9 Screening Reveals Squalene Epoxidase as a Susceptibility Factor for Cytotoxicity of Malformin A1.
Koizumi Y; Fukushima J; Kobayashi Y; Kadowaki A; Natsui M; Yamaguchi T; Imai Y; Sugiyama T; Kuba K
Chembiochem; 2019 Jun; 20(12):1563-1568. PubMed ID: 30734978
[TBL] [Abstract][Full Text] [Related]
4. Effect of interferon gamma and tumour necrosis factor alpha on sensitivity to cisplatin in ovarian carcinoma cell lines.
Clark S; McGuckin MA; Hurst T; Ward BG
Cancer Immunol Immunother; 1994 Aug; 39(2):100-4. PubMed ID: 8044830
[TBL] [Abstract][Full Text] [Related]
5. BSV163/DOPE-mediated TRAIL gene transfection acts synergistically with chemotherapy against cisplatin-resistant ovarian cancer.
Nguyen QM; Dupré PF; Berchel M; Ghanem R; Jaffrès PA; d'Arbonneau F; Montier T
Chem Biol Drug Des; 2024 Jan; 103(1):e14357. PubMed ID: 37731182
[TBL] [Abstract][Full Text] [Related]
6. Enzyme-Instructed Intracellular Molecular Self-Assembly to Boost Activity of Cisplatin against Drug-Resistant Ovarian Cancer Cells.
Li J; Kuang Y; Shi J; Zhou J; Medina JE; Zhou R; Yuan D; Yang C; Wang H; Yang Z; Liu J; Dinulescu DM; Xu B
Angew Chem Int Ed Engl; 2015 Nov; 54(45):13307-11. PubMed ID: 26365295
[TBL] [Abstract][Full Text] [Related]
7. Resistance Improvement and Sensitivity Enhancement of Cancer Therapy by a Novel Antitumor Candidate onto A2780 CP and A2780 S Cell Lines.
Mohammadi Hadloo S; Mohseni Kouchesfahani H; Khanlarkhani A; Saeidifar M
Rep Biochem Mol Biol; 2023 Oct; 12(3):374-385. PubMed ID: 38618266
[TBL] [Abstract][Full Text] [Related]
8. Investigating the Effects of Dorema hyrcanum Root Extracts on Selective Induction of Programmed Cell Death in Glioblastoma, Ovarian Cancer and Breast Cancer Cell Lines.
Hatami M; Sahranavard S; Bagheri F; Shahsavari Z; Salami S
Anticancer Agents Med Chem; 2024 Mar; ():. PubMed ID: 38482619
[TBL] [Abstract][Full Text] [Related]
9. Polyphyllin I Sensitizes Cisplatin-Resistant Human Cervical Cancer Cells to Cisplatin Treatment.
Zhang L; Liu W; Li Y; Fu Y; Xu C; Yu M
Nutr Cancer; 2024 May; ():1-10. PubMed ID: 38733116
[TBL] [Abstract][Full Text] [Related]
10. Supramolecular self-associating amphiphiles (SSAs) as nanoscale enhancers of cisplatin anticancer activity.
Dora NO; Blackburn E; Boles JE; Williams GT; White LJ; Turner SEG; Hothersall JD; Askwith T; Doolan JA; Mulvihill DP; Garrett MD; Hiscock JR
RSC Adv; 2021 Apr; 11(23):14213-14217. PubMed ID: 35423951
[TBL] [Abstract][Full Text] [Related]
11. p90RSK pathway inhibition synergizes with cisplatin in TMEM16A overexpressing head and neck cancer.
Yassin-Kassab A; Chatterjee S; Khan N; Wang N; Sandulache VC; Huang EH; Burns TF; Duvvuri U
BMC Cancer; 2024 Feb; 24(1):233. PubMed ID: 38373988
[TBL] [Abstract][Full Text] [Related]
12. Therapeutic potential of marine peptides in cervical and ovarian cancers.
Ahmed S; Khan H; Fakhri S; Aschner M; Cheang WS
Mol Cell Biochem; 2022 Feb; 477(2):605-619. PubMed ID: 34855045
[TBL] [Abstract][Full Text] [Related]
13. Malformin-A1 (MA1) Sensitizes Chemoresistant Ovarian Cancer Cells to Cisplatin-Induced Apoptosis.
Abdullah N; Tamimi Y; Dobretsov S; Balushi NA; Alshekaili J; Al Balushi H; Al Kindi M; Hassan SI; Bahlani SA; Tsang BK; Burney IA
Molecules; 2021 Jun; 26(12):. PubMed ID: 34199287
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of PTEN sensitizes human ovarian cancer cells to cisplatin-induced apoptosis in a p53-dependent manner.
Yan X; Fraser M; Qiu Q; Tsang BK
Gynecol Oncol; 2006 Aug; 102(2):348-55. PubMed ID: 16545436
[TBL] [Abstract][Full Text] [Related]
15. Arsenic trioxide and tetraarsenic oxide induce cytotoxicity and have a synergistic effect with cisplatin in paclitaxel-resistant ovarian cancer cells.
Byun JM; Lee DS; Landen CN; Kim DH; Kim YN; Lee KB; Sung MS; Park SG; Jeong DH
Acta Oncol; 2019 Nov; 58(11):1594-1602. PubMed ID: 31257975
[No Abstract] [Full Text] [Related]
16. Synergistic induction of apoptosis by the combination of trail and chemotherapy in chemoresistant ovarian cancer cells.
Cuello M; Ettenberg SA; Nau MM; Lipkowitz S
Gynecol Oncol; 2001 Jun; 81(3):380-90. PubMed ID: 11371126
[TBL] [Abstract][Full Text] [Related]
17. Disparities in Cisplatin-Induced Cytotoxicity-A Meta-Analysis of Selected Cancer Cell Lines.
Ćwiklińska-Jurkowska M; Wiese-Szadkowska M; Janciauskiene S; Paprocka R
Molecules; 2023 Jul; 28(15):. PubMed ID: 37570731
[TBL] [Abstract][Full Text] [Related]
18. Research progress on the premature ovarian failure caused by cisplatin therapy.
Li Z; Qi H; Li Z; Bao Y; Yang K; Min Q
Front Oncol; 2023; 13():1276310. PubMed ID: 38053654
[TBL] [Abstract][Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
